de Marinis, F.
372  Ergebnisse:
Personensuche X
?
 
?
3

OA21.05 Tepotinib + Osimertinib in EGFR-mutant NSCLC with M..:

Kim, T.M. ; Guarneri, V. ; Jye, V.P....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S94 , 2023
 
?
4

P1.25-09 TARGET: A Phase II Study of 5-year Adjuvant Osimer..:

Soo, R. ; De Marinis, F. ; Han, J.-Y....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S272 , 2023
 
?
5

92P Predictors, surrogate and patient-reported outcomes in ..:

Bertolaccini, L. ; Mohamed, S. ; Galetta, D....
Journal of Thoracic Oncology.  18 (2023)  4 - p. S94-S95 , 2023
 
?
 
?
 
?
9

OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage..:

Herbst, R.S. ; Wu, Y.-L. ; Grohe, C....
Journal of Thoracic Oncology.  18 (2023)  3 - p. e4 , 2023
 
?
11

OA15.04 Comparison of Digital Vs Manual PD-L1 Tumour Cell S..:

Herbst, R.S. ; Ruderman, D. ; Conway, J....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S79-S80 , 2023
 
?
12

EP07.04-06 ALK Rearrangement Is Associated with Early Lymph..:

Gallina, F.T. ; Tajè, R. ; Cecere, F.L....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S545-S546 , 2023
 
?
 
?
15

LBA4 Preliminary safety and efficacy of adagrasib with pemb..:

Jänne, P.A. ; Smit, E.F. ; de Marinis, F....
Immuno-Oncology and Technology.  16 (2022)  - p. 100360 , 2022
 
1-15